April 2, 2025 I New York City
Cancer Progress is returning as a live, in-person event in New York City!
This streamlined, one-day conference promises a focused and impactful experience. Attendees can expect unparalleled insights, in-depth issue coverage, and exceptional networking opportunities. The conference’s enduring success and value are driven by the expertise and reputation of its distinguished speaking faculty.
Join us for this dynamic gathering of experts for a thought-provoking exploration of the possibilities and challenges inherent in shaping the future of oncology.
100% of proceeds from ticket sales and sponsorships will directly support the Damon Runyon Cancer Research Foundation and its mission to fund high-risk, high-reward cancer research.
Questions? Email us at contact@lumanity.com.
Cancer Progress was started in 1989 with the goal of facilitating discussions of scientific progress within the context of development, regulatory, clinical, commercial and investment perspectives. Cancer Progress has historically featured two to three days of provocative, informative panel discussions with pivotal topics, frank discussions, vigorous debate, opportunities for audience questions and comments, and a partnering platform to enable meaningful connections and meetings with innovators, developers, and investors.
Cancer Progress 2025 Growing Speakers List
Axel Hoos MD, PhD
Peter Sandor MD, PHD
EVP, Head of Corporate Strategy
Astellas Pharma US
Kapil Dhingra MD
Managing Member
KAPital Consulting LLC
Francesca Barone MD, PhD
Chief Scientific Officer
Candel Therapeutics
John Wiggins
VP, Isotope Strategy Lantheus
Lucy Kappel PhD
Vice President, Head of Oncology Business Development, Regeneron Pharmaceuticals
Ashlee Cramer
Caregiver and advocate for cancer and GvHD, Social Influencer, Michael and Mom Talk Cancer
Michael Cramer
Cancer survivor, Patient advocate for cancer and GvHD, Social Influencer, Michael and Mom Talk Cancer
Dominique Verhelle PhD, MBA
Co-Founder & CEO, NextRNA Therapeutics
Joe Guidi
VP, Global Medical Early Differentiation and Pipeline, Bristol Myers Squibb
Lakshmi Srinivasan
Executive Director, Oncology, Translational Medicine, Moderna Tx
Amy Han
Vice President, Global Gommercialization, Solid Tumors, Genmab
Alan Bash
President, Carvykti, Legend Biotech
Kate Yen
Founder and CEO, Auron Therapeutics
Adriana Herrera
CEO, Pierre Fabre Pharmaceuticals, Inc.
Dr. Qasim I Ahmad
Chief Medical Officer, IO Biotech
Dora Mitchell PhD
SVP of Operations/Chief of Staff, Interius BioTherapeutics
Laura Johnson PhD
Chief Operating Officer/Scientific Officer, Head of R&D, Verismo Therapeutics
Moderators and Closing Speakers
Dennis Chang PhD
Senior Vice President, Strategy Consulting, Lumanity
Martin Strebl-Bantillo PhD
Principal, Strategy Consulting, Lumanity
Jeff Bockman PhD
Expert Advisor and EVP, Oncology, Strategy Consulting Lumanity
Ed Saltzman
Senior Strategic Advisor, Lumanity
Michael Parisi
Joint Global Practice Lead, Medical Strategy and Communications, Lumanity
Angela Wheeler
President, Insight US, Lumanity
Yung S. Lee PhD
President & CEO, Damon Runyon Research Foundation
Tom Murtagh
Global Practice Lead, Strategy & Insight, Lumanity
Viraj Parekh PhD
Principal, Strategy Consulting, Lumanity